Disclosed is a new method for improving the quality of platelets. It is disclosed for the first time that the molecular of carnitine palmitoyl transferase II (CPT2) of the platelet mitochondrial inner membrane is critical to the survival, preparation and storage of platelets, the reduction of CPT2 protein expression and/or activity seriously affects the quality of platelets, and the normal or high expression of the protein improves the quality of platelets. By means of directly and indirectly influencing or modifying CPT2 protein, the effect of CPT2 on platelets is verified at multiple angles, and a pathway and endogenous or exogenous molecules having a key effect of maintaining activity of platelets are disclosed. Therefore, the CPT2 itself or an up-regulator thereof can be used for maintaining the activity of platelets, and maintaining or improving the storage quality of platelets, and can also be used for screening substances capable of maintaining the activity of platelets or improving the storage quality thereof on the basis of the CPT2 or the signal pathway involving same and using same as a target.

The invention provides microglial cell comprising cortical organoid cultures, methods of generating the same and methods of use thereof for identifying therapeutic agents.

This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.

The present invention refers to a substantially pure population of pericytes, or cell suspension comprising pericytes, wherein the pericytes are at least 80% of the total cell population or suspension, characterized in that CMA is inhibited, for example by inhibiting the expression or deleting the gene LAMP2A. In a preferred embodiment, said population or suspension of pericytes is used as a medicament, for instance in the treatment of cancer, preferably glioblastoma.

The disclosure provides bovine-induced pluripotent stem cells along with compositions and methods for use in producing the same.

The present invention relates to methods of producing pancreatic endocrine cells and uses of the cells obtained using the methods. The method utilises inhibitors or combinations of factors to provide increased quantities of endocrine material, for example for transplantation purposes.

Compositions and methods are described herein for inducing reprogramming of non-pluripotent cells across lineage and differentiation boundaries to generate endodermal progenitor cells and hepatocytes. Compositions and methods for expansion of endodermal progenitor cells without loss of phenotype are also described herein.

The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.

An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) cAMP inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts.

This disclosure provides a chemically modified induced pluripotent stem (iPS) cell derived from parental cells and methods for generating the chemically induced pluripotent stem (iPS) cells, as well as cardiac progenitor cells capable of producing cells of multiple sub-lineages. The iPS cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue or to rejuvenating cardiac muscles in a patient in need thereof and to treat cardiac disease.